Congenital diaphragmatic hernia (CDH) is a life-threatening congenital anomaly characterized by pulmonary hypoplasia and persistent pulmonary hypertension of the newborn (PPHN). Despite advances in neonatal intensive care, management of pulmonary hypertension remains a major challenge, and the role of inhaled nitric oxide (iNO) in this population is still controversial.
This study evaluates the therapeutic efficacy and physiological responses to iNO in late preterm (34 weeks of gestational age or more) or term neonates with Bochdalek-type CDH and severe pulmonary hypertension who require mechanical ventilation but are not placed on ECMO within 14 days of life.
iNO will be initiated at 20 ppm, and serial measurements of oxygenation index, arterial blood gas, vital signs, cerebral oxygen saturation (NIRS), and echocardiographic indices will be performed to evaluate the short-term treatment response.
Age
0–0
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Bochdalek type congenital diaphragmatic hernia
Gestational age at 34 weeks or more and within 14 days after birth
Hypoxic respiratory failure and pulmonary hypertension
You may not be if
Combined congenital heart disease requiring neonatal intervention or surgery
Previous treatment of pulmonary vasodilators including inhaled nitric oxide